Literature DB >> 15180922

The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.

Roxana I Sufan1, Michael A S Jewett, Michael Ohh.   

Abstract

The majority of kidney cancers are caused by the mutation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL protein (pVHL) is part of an E3 ubiquitin ligase complex called VEC that is composed of elongin B, elongin C, cullin 2, NEDD8, and Rbx1. VEC targets a hypoxia-inducible factor (HIF) transcription factor for ubiquitin-mediated destruction selectively in the presence of oxygen. In the absence of wild-type pVHL, as in VHL patients or in the majority of sporadic clear cell renal cell carcinomas, HIF-responsive genes are inappropriately activated even under normoxia. Recent insights into the molecular mechanisms regulating the function of pVHL, and thereby HIF, in the context of kidney cancer are the focus of this review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180922     DOI: 10.1152/ajprenal.00424.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  19 in total

1.  VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.

Authors:  Lingchao Chen; Lei Han; Kailiang Zhang; Zhendong Shi; Junxia Zhang; Anling Zhang; Yongzhi Wang; Yijun Song; Yongli Li; Tao Jiang; Peiyu Pu; Chuanlu Jiang; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2012-05-30       Impact factor: 12.300

2.  NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.

Authors:  Roshan J Thapa; Peirong Chen; Mitchell Cheung; Shoko Nogusa; Jianming Pei; Suraj Peri; Joseph R Testa; Siddharth Balachandran
Journal:  Mol Cancer Ther       Date:  2013-05-08       Impact factor: 6.261

3.  Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.

Authors:  Hye-Sik Kong; Sunmin Lee; Kristin Beebe; Bradley Scroggins; Gopal Gupta; Min-Jung Lee; Yun-Jin Jung; Jane Trepel; Leonard Neckers
Journal:  Mol Pharmacol       Date:  2010-09-02       Impact factor: 4.436

4.  Metastatic Renal Cell Cancer-Systemic Therapy.

Authors:  Amit Joshi; Arvind Sahu; Vanita Noronha; Vijay Patil; Kumar Prabhash
Journal:  Indian J Surg Oncol       Date:  2018-01-29

5.  Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response.

Authors:  Irene I L Hwang; Ian R Watson; Sandy D Der; Michael Ohh
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

Review 6.  Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Authors:  Rekha A Kumbla; Robert A Figlin; Edwin M Posadas
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

7.  The role of components of the chromatin modification machinery in carcinogenesis of clear cell carcinoma of the ovary (Review).

Authors:  Hiroshi Shigetomi; Akira Oonogi; Taihei Tsunemi; Yasuhito Tanase; Yoshihiko Yamada; Hirotaka Kajihara; Yoriko Yoshizawa; Naoto Furukawa; Shoji Haruta; Shozo Yoshida; Toshiyuki Sado; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2011-05-16       Impact factor: 2.967

8.  Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists.

Authors:  Darwin L Lim; Raymond Ko; Stephen E Pautler
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 9.  Genomics of renal cell cancer-- does it provide breakthrough?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.